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New Information: Some of the PB vs. BM MRD data has been presented at previous EHA/ASH/iwCLL meetings but we
now present PFS and OS data also.
Background: Minimal residual disease (MRD) in CLL is an independent predictor of progression-free (PFS) and overall
survival (OS) with a high, intermediate and low risk of disease progression seen in patients with >1%, 0.01-1%, or
<0.01% MRD respectively. Evaluating novel treatments currently requires assessment of PFS/OS in randomised
controlled trials but the prolonged duration of remission means that this approach is slow. Assessing MRD as a trial
endpoint could greatly speed the process; using peripheral blood (PB) would be preferable but antibody therapies
preferentially deplete circulating disease to a variable extent and bone marrow (BM) is the more sensitive site for MRD
detection.
Aims: To compare PFS/OS according to MRD level in PB and BM for different treatment and patient groups and
determine the optimum site for MRD assessment.
Methods: MRD was quantified using multi-parameter flow cytometry according to ERIC consensus protocols with a limit
of quantification of 10-4 / 0.01% or better.
Results: The MRD level in 609 paired PB & BM samples taken during or within 6 months of treatment (446 in clinical
trials, see table) was concordant in 443 (72.7%) at MRD thresholds <0.01% / 0.01-1% / >1%. In 391 cases with <0.01%
PB MRD, 85/391 (21.7%) had 0.01-1% CLL and 14/292 (3.6%) had >1% CLL in the paired BM sample.  In 118 cases
with 0.01-1% CLL in the PB, the paired BM sample showed >1% CLL in 63/118 (53.4%). The PB MRD level would have
assigned a higher risk category than BM in only 4 cases, all of which had detectable BM disease. 
Discrepancies between PB & BM MRD levels were not consistent across treatment and patient groups. Refractory
patients treated with alemtuzumab-based therapies typically showed a high proportion of discrepant results with >1 log
differences while patients in CR/PR receiving alemtuzumab consolidation had few discrepancies; during Ibrutinib
monotherapy (IcICLLE trial) there have been no discordant cases to date.
To determine whether discrepant results impact on outcome, PFS/OS was evaluated according to PB & BM MRD in
different trials. In the ADMIRE/ARCTIC trials, PB & BM MRD levels were discordant in 66/312 evaluable cases, all with
墓0.01% BM but <0.01% PB MRD. After a median follow-up of 3 years, MRD level was confirmed as a strong predictor of
PFS and OS, independent of categorical response, with the presence of 墓0.01% MRD conferring a significantly poorer
outcome (PFS: HR 4.6, 95%CI 2.7 to 7.7, p=<0.001). For patients in CR, and with 墓0.01% MRD (n=70), 3 year PFS was
68.7% compared with 86.6% for patients with <0.01% MRD (n=176). There was no observable difference in the PFS or
OS for patients with <0.01% PB but 墓0.01% BM MRD compared to those with <0.01% PB & BM MRD. However, for
those patients with MRD detected in the BM only, there was a median of 0.08% CLL and this would be predicted to yield
observable differences in PFS only after >3 years follow-up. The results contrast with the outcome for 47 evaluable
patients in the CLL202 CAMFlud trial where patients with <0.01% MRD in PB but 墓0.01% disease in BM had a poor
outcome that was similar to those with 墓0.01% in both PB & BM, and both groups had significantly poorer PFS/OS than
patients with <0.01% MRD in both PB & BM (with median 18 months follow-up for patients with 墓0.01% in PB & BM /
<0.01% PB but 墓0.01% BM / <0.01% MRD in both PB & BM patients respectively, median PFS was 1.6 / 6.5 / 44.7
months and OS was 7.5 / 14 / not reached, P<0.001).
Image/Pictures:
Summary/Conclusion: Patients achieving <0.01% CLL have a better outcome than those with detectable MRD but the
power of peripheral blood MRD eradication to predict outcome varies widely according to the type of therapy received
and is poor with more potent antibodies. The most robust tissue and time-point for MRD assessment to predict long-term
outcomes in CLL is the bone marrow at 3 months post-treatment. Our work justifies the use of MRD eradication from the
marrow post-treatment as a surrogate end-point in clinical trials.
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